Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

3.3K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
3.3K
Chemical Synapses01:26

Chemical Synapses

12.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.2K
Chemical Synapses01:26

Chemical Synapses

6.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

Neurology·2026
Same author

Diagnostic and Screening Laboratory Tests in the Assessment of Patients With Small Fiber Neuropathy: An Evidence-Based Review-Report of the American Association of Neuromuscular and Electrodiagnostic Medicine Small Fiber Neuropathy Task Force.

Muscle & nerve·2026
Same author

Practice Pearls: Spinal Myxopapillary Ependymoma Masquerading as Charcot-Marie Tooth (CMT) Disease.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2025
Same author

Virtual EMG: Safe and Effective Remote Supervision and Reporting.

Muscle & nerve·2025
Same author

Idiopathic Inflammatory Myopathies and Malignancy Screening: A Survey of Current Practices Amongst Canadian Neurologists and Rheumatologists.

Muscle & nerve·2025
Same author

Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome.

Brain : a journal of neurology·2025

Related Experiment Video

Updated: Mar 10, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.1K

Toxic and Endocrine Myopathies.

Hans D Katzberg, Charles D Kassardjian

    Continuum (Minneapolis, Minn.)
    |December 7, 2016
    PubMed
    Summary

    Toxic and endocrine myopathies, including critical illness myopathy, stem from various causes. Early detection and management of underlying conditions like Cushing syndrome and thyroid disease are key to preventing neurological complications.

    Area of Science:

    • Neurology
    • Endocrinology
    • Toxicology

    Background:

    • Myopathies can arise from endocrine disorders and toxic exposures.
    • Critical illness myopathy is a significant concern in intensive care unit patients.

    More Related Videos

    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    9.6K
    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
    06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    20.8K

    Related Experiment Videos

    Last Updated: Mar 10, 2026

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    16.1K
    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    9.6K
    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
    06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    20.8K